$642 Million is the total value of Broadfin Capital, LLC's 51 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATEC | Exit | ALPHATEC HOLDINGS INC | $0 | – | -145,514 | -100.0% | -0.06% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -100,000 | -100.0% | -0.12% | – |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -358,295 | -100.0% | -0.16% | – |
| RTRX | Exit | RETROPHIN INCcall | $0 | – | -51,900 | -100.0% | -0.18% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -1,509,342 | -100.0% | -0.26% | – |
| CGNT | Exit | COGENTIX MED INC | $0 | – | -670,812 | -100.0% | -0.34% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -65,300 | -100.0% | -0.69% | – |
| IDRA | Exit | IDERA PHARMACEUTICALS INC | $0 | – | -2,030,604 | -100.0% | -0.70% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -366,300 | -100.0% | -1.64% | – |
| ENDP | Exit | ENDO INTL PLC | $0 | – | -2,442,323 | -100.0% | -3.09% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -1,150,119 | -100.0% | -5.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.